Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maya H. Maloney, Stephanie Payne, Jeph Herrin, Lindsey R. Sangaralingham, Nilay D. Shah, Andrew J. Barkmeier
Topics & Concepts
RanibizumabMedicineAfliberceptBevacizumabAdverse effectOphthalmologyClinical PracticeInternal medicineChemotherapyFamily medicineRetinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeOphthalmology and Visual Impairment Studies